Clinical Research Directory
Browse clinical research sites, groups, and studies.
Metronomic Chemotherapy by Cyclophosphamide Versus Megestrol in Palliative Cancer
Sponsor: Centre Oscar Lambret
Summary
The scope of the trial is to assess the free progression rate at 2 months for each group of patients.
Official title: A Phase II Randomized Study to Assess the Benefit of a Metronomic Chemotherapy by Cyclophosphamide Versus Megestrol in Palliative Cancer
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
88
Start Date
2009-09-25
Completion Date
2011-01-19
Last Updated
2026-09-17
Healthy Volunteers
No
Conditions
Interventions
CYCLOPHOSPHAMIDE
50 mg x 2 /day , per os, nonstop until disease progression or toxicity or patient decision
MEGESTROL
320 mg/day, per os, 2 pills of 160 mg one time, nonstop until disease progression or toxicity or patient decision
Locations (4)
Centre Oscar Lambret
Lille, France
Hopital Saint Vincent
Lille, France
Centre Hospitalier Regional - Dermatology
Lille, France
Centre Hospitalier Regional - Oncology
Lille, France